Guardsman Technology

Guardsman’s Echocardiography Management System (“GEMS”), a clinically validated patient management system*, is designed to acquire and use patient-specific data points of cardiac function to assess and recommended hemodynamic management strategies. Unlike existing cardiac monitoring devices, GEMS is able to assess a wide spectrum of functional clinical parameters of the heart such as cardiac output, filling pressures, contractility and valvular function. Given its unique and compelling capabilities and outcomes, GEMS should be a key device located in all acute points of care (OR, ICU, ER, medical-surgical units), as well as in outpatient and home care settings.

Consisting of a proprietary method, software, a hands-free transducer and a disposable patient securing patch, GEMS is uniquely positioned to be a primary product line or to be an upgrade module for existing cardiac monitoring device consoles.

Key Features of GEMS Method, Software and Hardware:

• Noninvasive
• Ease of use for medical professionals
• Simple user interface
• Hands-free image acquisition
• Unique dual plane transducer to monitor and guide patient management
• Multi-functional proprietary ultrasound platform
• Medical grade low-energy wireless capability

 *DISCLAIMER: GEMS Technology has not yet been approved  for clinical use by regulatory agencies.  

 Guardsman patented method has been proven*(1,2) to be clinically feasible and effective for:

• Identifying patients with or at risk of developing heart failure (HF)
• Reducing the incidence of post-operative HF (an 18-fold reduction) 
• Reducing the incidence of post-operative atrial fibrillation
• Reducing the amount of perioperative intravenous fluids, safely
• Reducing the length of post-operative hospital stays by 43%
• Potentially reducing the overall cost of care

Note: Guardsman method has been proven to be safe as evidenced by showing no increased risk of developing renal, neurologic or other cardiovascular complications when compared to current standards of care.

*References:

1. Internal proprietary data.

2. Echocardiograhy-based hemodynamic management of left ventricular diastolic dysfunction: A feasability and safety study. Shillcutt, SK, et al. Echocardiography, 2014;00:1-10.

DISCLAIMER: GEMS Technology has not yet been approved for clinical use by by regulatory agencies.